The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
good snapshot of the TATA Grp and TATA Sons, I was wrong mcap is *slightly* higher than $7Bn, it's £145Bn.
https://www.linkedin.com/pulse/why-isnt-ratan-tata-richest-businessman-india-dr-shashank-shah/
What isn't covered on that link is the mountain of debt, mostly motors and steel.
Looking at those figures for TATA MD I can't see any investment for several years. Typical Covid launch, ramped up headcount far in excess of revenues, now they need to ramp up revenues quickly to pay for headcount but revenue will mostly have to be non covid new business. I'm sure it'll be £100mm PA in no time, just like NCYT.
So what happened between 11/20 and 04/2 they spent 5-6mths discussing the 'issues' and NCYT offered a £20mm fix IIRC. So how did NCYT get to the point of offering a fix, what problem was their fix going to resolve, and the big question is who was going to be liable for the £20mm.
Hard to know what the mean/ave sp is for holders, but aye I'd say £3-5 would cover most people. But it would/will be a tough climb, I suspect there's a load of cash invested at £1.5-2.5 so could be stuck there for a while. It's a volatile market in a crazy world anything could happen
Mostly interested to see how the SP acts next week, when HMG settled prev the SP rise fizzled out over a few days. Lots of bullish comments on the ABDX bb future growth, Covid rising too, wonder if the SP will find support
thread ob Biosynex bourse bb
https://www.boursorama.com/bourse/forum/1rPALBIO/detail/461534724/
05 Oct 2022 • 17:43
Novacyt +8+9
Eurobio +5+6
Biosynex +7+8
The cac is red
Back Covid scares
Together with various crises
Latest Company review on Glassdoor https://www.glassdoor.ie/Reviews/Novacyt-Group-Reviews-E3343371.htm
"Pros
The small number of core people who cared and wanted to help and support end-users in challenging times.
Cons
Higher management (now departed CCO for example) had little post-Covid actions/plans. Proposals of alternative areas to grow into (from sales teams on numerous occasions) were not recognised until it was very evident that covid testing demands were on the downturn. It’s unfortunate that there was lack of future planning based on utilising instrument install base to leverage the promate solution/technology within public and private sectors.
The portfolio of RUO assays was strong but needed updated. If they were maintained it would have given a strong start to post covid markets prior to gaining CE-IVD/IVDR
There was a toxic working environment within and between some commercial divisions.
The lack of a proper e-commerce platform is telling of the position of where Novacyt currently is.
Advice to Management
Listen to your employees, the feet on the street; they will guide you to what’s needed.
Also, when making people redundant - without including the sales or management team, who should also be included for proposed cuts - don’t award yourselves a big bonus, the current results don’t warrant it."
It describes a toxic culture internally. But that's a very fixable thing. The business failings are not reacting quick enough to market conditions. That is also fixable.
It's a 4-6Q job, but no reason not to turn the business around.
*on the Theradiag*
Also share buybacks are gone, it was never a good idea, akin to buying a $1 for $1.20, it only ever facilitated BoD bonuses and real life interest rates will end it.
Getting the SP to ~1.60 was the fault of the BoD everything else is circumstance, if you are genuinely invested in NCYT and don't need your money back for a few years don't panic NCYT still has a good business DNA, check out their history, no reason for them not to be able work their way out of this current situation and turn a corner